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ABSTRACT 
Objective: The aim of this study is to prepare floating hollow microspheres encapsulating Sorafenib (SFN) to enhance its oral bioavailability.  
Methods: Gastro-floating hollow adhesive microspheres containing SFN were produced by using an emulsion solvent evaporation technique with 
ether and ethanol as solvents. Ethyl cellulose and carbopol 934P were used as the encapsulating carriers. The effects of formulation parameters like, 
solvent volume ratio, and drug to polymer ratio (D: P ratio), encapsulation efficiency percentage EE%, floating percentage, and release of SFN after 
12 h (Rel12) were investigated and analyzed using a (32) full factorial design.  
Results: The floating percentage of the microspheres was found to be 76.5%. The in vitro drug release from these hollow microspheres followed the 
Higuchi model equation. The in vivo results showed that approximately 1.96-fold improvement in the relative bioavailability of the microspheres 
compared with that of the commercial tablet.  
Conclusion: The results demonstrate that the hollow microspheres with good gastro-floating ability are a promising delivery system to enhance 
SFN bioavailability. 
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Sorafenib (SFN) is an endorsed drug to treat hepatocellular 
carcinoma (HCC) [1]. SFN is a multi-kinase inhibitor that prolongs 
overall survival and postpones the opportunity to progression in 
patients with advanced HCC who are not candidates for remedial 
treatment [2]. SFN is a weakly basic drug with a higher absorption 
rate under acidic conditions in the stomach than in the intestine [3]. 
Floating drug delivery systems are a dosage formulation that floats 
on the gastric juice and persistently releases the drugs [4]. The 
floating systems show a bulk density of less than gastric fluids and 
remain buoyant in the stomach for a longer period of time without 
affecting the gastric emptying rate [5]. The drug is released slowly 
when the system floats in the gastric fluid at the desired rate [6]. 
This results in increased gastric retention time and better control of 
fluctuations in the plasma drug concentration [7]. A floating drug 
delivery system could be suitable for SFN with a definite absorption 
zone in the stomach [7]. 
Orally administrated SFN exhibited large individual differences in 
bioavailability because of the variable gastrointestinal transit time of 
a single tablet [8]. On the contrary, a multiple-unit floating drug 
delivery system could reduce inter-and intra-subject variability in 
drug absorption and dose dumping [9, 10]. There is no report on 
SFN containing hollow microspheres. 
Hollow microspheres are multi-unit floating formulations that 
release the drug more uniformly when passing through the 
gastrointestinal tract [11]. The more uniform the distribution of 
these multi-unit microspheres in the gastrointestinal tract, the more 
reproducible the drug absorption and the less local irritation caused 
[12, 13]. 
Herein, as illustrated in Scheme 1, we provide a protocol to prepare 
gastro-floating hollow adhesive microspheres of EC/Carbopol 934P 
encapsulating SFN in order to achieve a sustained release of drug in 
the stomach. Ethyl cellulose (EC) was used as the polymer because 
of its water insolubility, which will help in sustaining the drug 
release for a longer time [14]. Carbopol 934P is an anionic polymer 
with mucoadhesive properties [15]. 
The objective of this study was to develop floating gastro-retentive 
hollow adhesive microspheres to increase their residence time in the 
stomach, which may result in an enhanced bioavailability. 
 
 
Scheme 1: Illustration of the preparation process of the gastro-floating hollow adhesive microspheres of EC/Carbopol 934P encapsulating SFN 
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MATERIALS AND METHODS 
Chemicals and reagents 
SFN and EC (Sigma Chem. Co., St. Louis. USA); Carbopol 934P (United 
States Lubrizol); Span 80, and cyclohexane Sigma Chem. Co., 
Stoneham (Germany); Liquid paraffin, and magnesium stearate (El-
Gomhoria Chem. Co., Ltd). Anhydrous ethanol, anhydrous diethyl 
ether, hydrochloric acid, N-hexane, ammonium acetate, acetonitrile 
and acetone, El-Nasr Pharm. Chem. Co., Ltd).  
Design of the experiment 
In the pre-optimization studies, the optimal concentrations of Span 
80 and magnesium stearate were investigated based on the results 
got from drug loading encapsulation efficiency and appearance. A 
two-factors, three-levels full factorial design (FFD) was employed to 
optimize the composition of the gastro-floating microspheres [16, 
17]. The experiments were performed in triplicate. The D: P ratio 
(A), and ether to ethanol volume ratio (B) were independent 
variables at three levels. The percentage drug entrapment efficiency, 
percentage drug floating and percentage release after 12 h were 
selected as the dependent variables. Table 1 shows the full factorial 
design. The significance levels of different influencing factors were 
tested by range comprehensive analysis. 
Preparation of microspheres 
Emulsion solvent evaporation technique was used to prepare the 
floating hollow adhesive microspheres containing SFN [18]. Briefly, 
polymer blends of EC and carbopol 934P were dissolved in a mixture 
of ethanol and diethyl ether. The required amount of SFN was 
dispersed into the solution with stirring at 10 °C. The polymer and 
drug solution was added slowly to liquid paraffin containing Span 80 
and magnesium stearate (soothing agent) with stirring at 400 rpm 
for 30 min at 10 °C until a stable emulsion was formed. The resulted 
emulsion was continuously stirred at 30 °C for 45 min. During this 
period, the volatile solvent evaporated and microspheres were 
obtained. The microspheres were filtered and washed with n-hexane 
and kept overnight at 30 °C. The dried microspheres were stored in 
desiccators at room temperature until use. 
 
Table 1: (32) Full Factorial design of different formulae of SFN microspheres 
Ether: ethanol (B) (v/v) Drug: polymer ratio (A) Formula No. 
7.5: 2.5 (-1) 0.15: 1 (-1) F1 
7.5: 2.5 (-1) 0.20: 1 (0) F2 
7.5: 2.5 (-1) 0.25: 1 (1) F3 
8: 2 (0) 0.15: 1 (-1) F4 
8: 2 (0) 0.20: 1 (0) F5 
8: 2 (0) 0.25: 1 (1) F6 
8.5: 1.5 (1) 0.15: 1 (-1) F7 
8.5: 1.5 (1) 0.20: 1 (0) F8 
8.5: 1.5 (1) 0.25: 1 (1) F9 
 
Independent variables Level 
-1 = 7.5: 2.5 0 = 8: 2  +1= 8.5: 1.5 Ether: Ethanol (v/v) 
-1 = 0.15: 1 0 = 0.20:1  +1= 0.25:1 Drug-polymer ratio 
 
Particle size and shape 
The size distribution of the microspheres was determined using an 
optical microscope (Leica Microsystems, Heerbrugg, Switzerland). 
Microsphere morphology and shape was described in terms of 
aspect ratio (AR) and circularity (C). The mean size distribution was 
calculated by measuring 200–300 particles. 
Microsphere morphological examination was also performed using 
scanning electron microscopy (SEM, Jeol, JSM-5200, Tokyo, Japan) at 
15 keV. Samples of dried floating hollow microspheres were 
mounted onto stubs and sputter-coated with gold in a vacuum 
evaporator. 
Determination of encapsulation efficiency and drug loading 
The encapsulation efficiency percentage (EE %) was calculated 
according to the following equation: 
 
Where W1 is the total amount of drug in the microsphere and W2 is 
the total quantity of the drug added initially. The drug loading (DL) 
of the hollow microspheres was calculated as follows [19]: 
DL (%)  =  (mass of SFN in microsphe  
The SFN-loaded hollow adhesive microspheres (10 mg) were ground 
and immersed into 10 ml of phosphate buffer pH 7.4. After ultra-
sonication, the concentration of SFN was determined using a UV-
visible spectrophotometer (Shimadzu UV-1700 series) at 265 nm. 
In vitro floating ability 
The floating behavior of the SFN microspheres was studied 
according to the method described in a previous report [11]. Briefly, 
100 individual microspheres were added to 900 ml of enzyme-free 
simulated gastric fluid (HCl/NaCl solution containing the surfactant 
Tween-80 at a concentration of 0.02%; pH 1.2) or enzyme-free 
simulated intestinal fluid of pH 7.4 (KH2PO4/NaOH solution 
containing 0.02% Tween-80) at 37 T 0.5 °C. The dispersing medium 
was agitated at 100 rpm with a standard paddle. The floating ability 
was evaluated based on the number of microspheres that remained 
buoyant in the medium. 
In vitro drug release studies 
Dissolution testing of the prepared microspheres equivalent to 50 
mg of SFN was performed with the rotating basket apparatus 
according to USP XXIV apparatus 2 [19].  
First, 900 ml of 0.1N HCl, was used as the release medium for 12 h. 
An amount of floating hollow microspheres equivalent to 50 mg of 
SFN was placed in a muslin cloth having a smaller mesh size than the 
microspheres. The mesh was tied with a nylon thread to avoid the 
escape of any microspheres, and a glass bead was placed in the mesh 
to induce sinking of the microspheres in the dissolution medium. 
Filtered samples, 3 ml each, were removed at 1, 2, 4, 6, 8, 10, and 12 
h. The samples were diluted appropriately with the release medium, 
and absorbance was measured at 265 nm. For SFN using a UV 
spectrophotometer (Shimadzu UV-1700 series). The withdrawn 
samples were replaced with equal volumes of the release medium 
kept at 37 °C. All experiments were conducted in triplicate [20]. The 
data acquired from the release studies were analyzed kinetically 
using various mathematical models including zero-order, first-order, 
and Higuchi models [21, 22]. 
Pharmacokinetic studies 
Male healthy rats weighing 280±20 g were selected randomly and 
divided equally into two groups (n = 6). All animal procedures were 
performed after approval by the Institutional Animal Care and Use 
Committee of Faculty of Pharmacy, Minia University, Minia, Egypt. 
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Rats were fasted for 24 h prior to drug administration and water 
was freely available. One group was given gastric lavage with 
ordinary tablets (tablets were ground into a fine powder, 0.5% CMC-
Na solution was suspended), and the other group was given the self-
made microsphere suspension (0.5% CMC-Na solution suspension) 
with the dose equivalent to 10 mg kg-1 SFN. Blood samples (0.5 ml) 
were collected by retro-orbital puncture at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12 and 24 h after administration. Then, plasma was obtained from 
the blood samples by centrifugation at 4000 rpm for 10 min. The 
concentration of SFN in rat plasma was determined by HPLC on C18 
column using a mobile phase of acetonitrile and 20 mmol/l 
ammonium acetate in a proportion 53:47 (v/v) pumped at a 
constant flow rate of 1.2 ml/min. Quantification was performed at 
265 nm [22].  
RESULTS AND DISCUSSION 
Preparation of floating hollow adhesive microspheres 
The emulsion solvent diffusion evaporation method was employed 
to develop SFN containing hollow microspheres as a floating drug 
delivery system. Liquid paraffin was used as the dispersion medium, 
and a mixture of ether and ethanol was used as the internal phase 
[23]. The ether could quickly diffuse into the liquid paraffin, 
resulting in a polymer instantly solidifying into a thin film. The 
microspheres exhibited better morphology when the ratio of inner 
and outer phases was 1: 10. When the internal phase ratio was 
increased, the microspheres became more cohesive. EC was used as 
the carrier polymer to sustain the drug release for a longer time with 
film-forming ability and stability in the stomach. Carbopol 934P is an 
anionic polymer with adhesive properties [24]. 
Microspheres appearance, drug loading amount and encapsulation 
efficiency of SFN are affected by Span 80 concentration, which acted 
as an emulsifying agent. Drug loading amount was elevated with 
increasing content of Span 80 up to 1.5%. However, once the 
concentration exceeded 1.5%, the appearance of the microspheres 
was irregular and slightly conglutinated. 
Magnesium stearate acted as a droplet stabilizer to prevent droplet 
coalescence during emulsification and solvent evaporation, and its 
concentration in liquid paraffin was varied to explore its effects on 
the appearance, drug loading amount and encapsulation efficiency of 
the microspheres [18]. The microsphere appearance was spherical 
without conglutination when the magnesium stearate concentration 
was adjusted to 0.02%. 
Characterization of the microspheres 
The particle size distribution of the microspheres is shown in fig. 1 
and the mean diameter was around 362 um. The morphology of the 
surface and was confirmed by SEM. The SEM photographs in fig. 2A 
and B revealed that the microsphere was spherical with a smooth 




Fig. 1: The size distribution of the gastro-floating hollow adhesive microspheres (mean±SD, n = 5) 
 
 
Fig. 2: Scanning electron microphotographs of a floating hollow adhesive microsphere 
 
The results of the optimization 
Table 2 shows the range analysis results of the effects of different 
factors. For the (32) factorial design, nine experimental trial 
formulations were proposed. Range analysis was used to clarify the 
effects of different factors on encapsulation effciency, floating 
effciency and SFN release after 12 h. The range value (R) for each 
factor was the difference between the maximal and minimal values 
of three levels. A higher R-value of a factor represents its greater 
effect on the encapsulation efficiency, floating efficiency and SFN 
release, and vice versa. Thus, the factors eliciting the above values in 
order were B (the ether/ethanol volume ratio), B (the drug to 
polymer ratio). According to the K values of the two factors, the 
optimum condition was B0A1, corresponding to 0.20: 1 ether/ethanol 
volume ratio, and 8.5: 1.5 D: P ratio. Three batches of microspheres 
were prepared based on the optimized formulation, and their 
physicochemical characteristics were studied in vitro. The optimized 
microspheres containing SFN exhibited an entrapment efficiency of 
82%, floating percentage of 78% and release after 12 h 92%.  
Encapsulation Efficiency 
The effect of changing the drug to polymer ratio on EE% was 
investigated, at each D: P ratio, using the ANOVA test. The EE% 
ranged from 67.7±3.8 to 95.6±5.36. The output shows the results of 
fitting a multiple linear regression model to describe the 
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Since the P-value in the ANOVA table is less than 0.05, there is a 
statistically significant relationship between the variables at the 
95% or higher confidence level. The output shows the results of 
fitting a multiple linear regression model to describe the 
relationship between the ether: ethanol ratio and drug EE%. The 
equation of the fitted model is 
 
…… Eq.2 
There is a statistically significant relationship between the variables 
at the 99% confidence level (***P>0.01).  
The 3-D plot (fig. 3) showed that. The improvement in EE% with 
increased ether: ethanol ratio was due to the fact that more amount 
of the drug get dissolved and incorporated in the polymer matrix as 
ether volume increased. EE% decreased from 83.2±4.10 to 
67.7±3.80 and from 95.6±5.36 to 79.6±4.98 at lower and higher 
levels of D: P ratio with constant ether: ethanol ratio. These results 
are because of decreased polymers concentration that allows less 
amount of SFN to be microencapsulated within the polymer matrix. 
  
Table 2: Factor combinations and response parameters of SFN microspheres prepared as 32 factorial design 
Formulation no. Factors EE% (% w/w)a Floating percentage (%)a Rel12a 
A B 
F-1 0.15: 1 (-1) 7.5: 2.5 (-1) 83.2±4.10 68.43±1.21 57.15±2.76 
F-2 0.15: 1 (-1) 8.0: 2.0 (0) 89.3±4.24 93.07±1.04 65.06±2.65 
F-3 0.15: 1 (-1) 8.5: 1.5 (1) 95.6±5.36 95.23±1.32 76.03±2.63 
F-4 0.20: 1 (0) 7.5: 2.5 (-1) 73.7±6.03 62.32±1.62 61.31±2.89 
F-5 0.20: 1 (0) 8.0: 2.0 (0) 80.5±4.59 70.23±1.65 79.98±3.01 
F-6 0.20: 1 (0) 8.5: 1.5 (1) 82.1±3.76 80.09±1.85 88.27±3.67 
F-7 0.25: 1 (1) 7.5: 2.5 (-1) 67.7±3.80 65.31±1.33 79.27±2.46 
F-8 0.25: 1 (1) 8.0: 2.0 (0) 72.5±3.22 75.25±1.08 87.41±1.87 
F-9 0.25: 1 (1) 8.5: 1.5 (1) 79.6±4.98 81.21±1.55 94.89±2.01 
mean±SD, n = 5, the parentheses in the data represent the decoded factor levels. A represents D: P ratio; B represents the ether: ethanol ratio. EE% = 
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Fig. 4: Three-dimensional plot for the effect of D: P ratio (A) and ether: ethanol ratio (B) on floating % 
 
In vitro floating study 
The floating test was used to investigate the floating ability of the 
hollow gastro-floating microspheres. The in vitro floating efficiency 
investigation showed that over 76.5% of the SFN hollow 
microspheres remained floating in the simulated gastric fluid for 12 
h. This might contribute to the sustained release of SFN 
encapsulated in the microspheres.  
The 3-D plot (fig. 4) showed that the improvement in floating 
percentage with increased ether: ethanol ratio may be for fast 
evaporation of ether content as its ratio increased. EE% decreased at 
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lower and higher levels of D: P ratio with constant ether: ethanol 
ratio. These results are because of decreased polymers content and 
consequently decreased microspheres density that allows buoyancy 
of the hollow microspheres for a long period of time. 
In vitro release study 
The best formulae for the in vitro release after whole dissolution 
period (12 h) were observed to be F9, F6, F8, F5, F7, F3, F2, F4, and 
F1. The equation of the fitted model which study the effect of D: P 
Ratio (A) and ether: ethanol ratio (B) on drug release after 12 h 
is  Since the P-value in 
the ANOVA table is less than 0.01 (**P>0.01), there is a statistically 
significant relationship between the variables at the 99% confidence 
level. The D: P ratios as well as ether: ethanol ratio were found to 
have a positive influence on the drug release. The response surface 
plot (fig. 5) illustrate that the percentage drug release at the end of 
12 h decreased from 57.15±2.76±1.54% to 79.27±2.46±1.23and 
from 76.03±2.63 to 94.89±2.01±1.42% at low and high levels of D: P 
ratio, respectively as the polymer content decreased. This can be due 
to increased diffusion of the drug from polymeric matrices, which 
left behind fewer drug crystals on the surface with the decrease in 
the polymer content. 
The levels of ether: ethanol ratio were found to have a positive 
influence on the drug release after 12 h. It was evident from the 3-D 
plots that the percentage drug release increased from 57.15±2.76 to 
76.03±2.63 and from 79.27±2.46 to 94.89±2.01 at low and high 
ether: ethanol ratio respectively, fig. 5. This increase in drug release 
was due to the increase in ether content, which upon evaporation 
increased the permeability of the polymer matrix. 
The release data of SFN from floating microspheres prepared with 
different process variables were analyzed according to zero and 
first-order kinetics as well as, Higushi diffusion-controlled 
mechanism table 3. The release order of the drug was determined. It 
was found that the drug was released from the microspheres 
according to Higushi diffusion pattern, at different drugs to polymer 
ratios. The release medium dissolves the drug after penetrating the 
microcapsule wall by allowing the dissolved drug to diffuse out due 
to concentration gradient established between the interior of the 
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Fig. 5: Three-dimensional plot for the effect of D: P ratio (A) and Ether: Ethanol ratio (B) on release 12 h % 
 
Table 3: Analysis of the release data for SFN microspheres 
Formula no. F1 F2 F3 F4 F5 F6 F7 F8 F9 
Zero-order Kz 8.148 10.50 7.108 8.837 8.781 9.482 6.44 5.215 9.323 
Rz 0.924 0.990 0.967 0.976 0.971 0.985 0.960 0.976 0.976 
First-order Kf 0.139 0.291 0.127 0.171 0.167 0.217 0.104 0.074 0.203 
Rf 0.962 0.942 0.952 0.960 0.958 0.966 0.948 0.946 0.963 
Higuchi equation Kh 21.26 18.70 33.09 29.24 19.98 23.75 22.16 17.90 31.69 
Rh 0.984 0.991 0.968 0.981 0.984 0.989 0.961 0.979 0.986 
Kz (mg. h-1), Kf (h-1) and Kh (mg/cm2. h½) are the release rate constants of zero–order, first order, and Higuchi model kinetics, respectively, as well as 
Rz, Rf and Rh are their corresponding correlation coefficients. 
 
Table 4: Pharmacokinetic parameters of SFN commercial tablets and microspheres after oral administration at 10 mg kg-1 in rats 
Parameter Commercial tablet Microspheres 
t1/2 (h) 11.87±5.21 16.42±7.52 
AUC 0-t (µg ml-1 h-1)  5.61±0.45 9.68±0.42 
AUC 0-∞ (µg ml-1 h-1)  6.89±0.95 13.47±1.23 
Tmax (h)  3.15±0.87 6.35±1.34 
Cmax (µg ml-1)  0.62±0.12 0.53±0.10 
MRT0-t (h)  8.51±1.65 11.08±0.9 
MRT0-∞ (h)  14.43±3.65 19.78±5.54 
ᵅ P>0.05 
mean±SD, n = 6 
 
Pharmacokinetic studies 
The study of pharmacokinetics in vivo could reveal the process and 
characteristics of drug absorption and metabolism in vivo. In this study, 
the self-made microspheres were used as a test product and compared 
with a reference product to study the pharmacokinetics in rats, and the 
relative bioavailability of the self-made preparations was enhanced. 
After the plasma samples were processed, the blood concentration-time 
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data of the commercially available tablets and self-made microspheres 
were obtained. Table 4 shows the relevant pharmacokinetic parameters 
and fig. 6 depicts the average plasma concentration-time curves of the 
preparation. SFN from the reference tablet diffused into the systemic 
circulation (Tmax = 3.15 h), while SFN release from the floating 
microspheres was significantly prolonged (Tmax = 6.35 h). 
 
 
Fig. 6: Profiles of mean plasma drug concentration-time after oral administration of SFN commercial tablet and microspheres (mean±SD, n = 6) 
 
As compared with the reference tablet, the microspheres exhibited a 
decreased Cmax and increased MRT. These data indicated that the Cmax of 
the encapsulated SFN microspheres was lower than that of the common 
tablets. In addition, the peak time was delayed, and the retention time of 
the drug in vivo was also prolonged. The pharmacokinetic parameters 
are shown in table 4. T-tests for ln AUC0–t and ln Cmax showed that there 
were significant differences between the SFN microspheres (*P>0.05) 
and ordinary tablets. Specifically, the peak concentration (Cmax) was 
decreased, the peak time (Tmax) was delayed, and the mean retention 
time (MRT) of the drug was prolonged. The relative bioavailability of 
SFN in the microspheres floating in the stomach was 196.0% at the same 
dose as the commercially available tablets. 
CONCLUSION 
Hollow microspheres could exhibit excellent floating and sustained 
release characteristics in vitro and improve SFN bioavailability in 
rats. The microspheres were prepared by an emulsion solvent 
evaporation technique using ether and ethanol as solvent, ethyl 
cellulose, and carbopol 934P as the encapsulating carrier. The 
optimized hollow microspheres with SFN showed high entrapment 
efficiency with small particle size diameter. The in vitro floating 
percentage of the microspheres was found to be 76.5% and floating 
after 12 h, which ensured that the majority of the drug encapsulated 
in the hollow microspheres remained in the stomach. It could be 
observed from the SEM investigations that the core was hollow, 
which conferred buoyancy. The results of the pharmacokinetic study 
in rats with a high AUC 0-t and prolonged Tmax together 
demonstrated the enhanced bioavailability because of the prolonged 
gastric retention and sustained drug release. 
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